Date of Abstract presentation11th December 2023IndicationsDiffuse large B-cell lymphoma (DLBCL)Abstract Number4496Abstract typePoster
Diffuse large B-cell lymphoma (DLBCL) stands as a swiftly progressing and aggressive ailment, representing the predominant type of non-Hodgkin lymphoma (NHL) and encompassing one-third of all diagnosed cases. Over two-thirds of DLBCL patients face either non-response or relapse after second-line treatment. Those experiencing relapse or inadequate response to initial interventions confront a scarcity of conventional treatment choices that offer sustained remission, leading to a median life expectancy of approximately six months. This ...